Teva to raise $34bn in new equity and debt for Allergan bid

Israeli pharmaceutical company Teva has 15 days to raise $33.75bn of funds to buy US firm Allergan's generics business.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: